A Phase 4 interventional study of Clindamycin and Diary in Bladder Carcinoma, Refractory Bladder Carcinoma and Urinary Tract Infection, sponsored by Roswell Park Cancer Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Roswell Park Cancer Institute · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 883 studies in Urinary Bladder Neoplasms with a site in United States — 162 open to participants now, 269 under way, 31 of them phase 3. Urinary Bladder Neoplasms · United States.
Among the 883 studies in Urinary Bladder Neoplasms with a site in United States, this one is the 230th largest by enrollment of the 715 interventional ones that give a count, is one of 53 that started in 2020, is one of 7 in phase 4, and was the 607th registered.
1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →162 of the 883 studies in Urinary Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+
SystImmune Inc. · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
883 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 281 · Phase 2 330 · Phase 3 88 · Phase 4 7
First in 1988; this study’s year is marked. 53 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is above the median of 60 across 1,299 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 46 across the 715 interventional studies, 180 across the 145 observational. Of the 562 that completed or were terminated, 253 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
314 of 883 have an industry lead sponsor. The 10 most frequent:
Roswell Park Cancer Institute is the lead sponsor of 419 studies on the registry; 65 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 21 (55%) have results posted.
Roswell Park Cancer Institute has 9 studies filed under Urinary Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
97 of the studies in Urinary Bladder Neoplasms with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06111235Phase 3CG Oncology, Inc.A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | 2026-11 |
| NCT04658862Phase 3Janssen Research & Development, LLCA Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | 2026-12-30 |
| NCT06525571Phase 3Johns Hopkins UniversityOutcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection | 2027-01-04 |
| NCT05911295Phase 3Seagen, a wholly owned subsidiary of PfizerDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | 2027-01-29 |
| NCT04241185Phase 3Merck Sharp & Dohme LLCEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | 2027-01-31 |
Add all 97 to your calendar (.ics) → With an account.
Among the 883 studies in Urinary Bladder Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial investigates whether a one-month course of preventative (prophylactic) antibiotics helps to reduce urinary tract infections after robot-assisted surgery to remove all of the bladder as well as nearby tissues and organs (radical cystectomy). Urinary tract infections are a common occurrence after robot-assisted radical cystectomy. Antibiotics such as trimethoprim-sulfamethoxazole or nitrofurantoin may prevent or control infections in patients with urinary tract infection and may help improve their response to radical cystectomy. Information gained from this study may help researchers to predict patient complications and identify better ways to manage these complications.
PRIMARY OBJECTIVE:
I. To determine if the utilization of a prophylactic antibiotic during the postoperative period will decrease the rate of urinary tract infection (UTI) post robot-assisted radical cystectomy.
SECONDARY OBJECTIVE:
I. To identify pre- and post-operative factors that may be associated with the development of a 90-day UTI following radical cystectomy.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I (ANTIBIOTIC): Patients receive ertapenem Intravenously (IV), levofloxacin, or clindamycin IV at induction per standard of care. At the time of full diet, patients receive trimethoprim-sulfamethoxazole PO daily or nitrofurantoin PO daily on days 1-30. Patients complete a drug diary for each day they receive the antibiotic.
GROUP II (CONTROL): Patients receive ertapenem IV, levofloxacin IV or clindamycin IV at induction per standard of care.
After surgery, patients are followed up to 120 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care. At the time of full diet, patients receive trimethoprim-sulfamethoxazole PO daily or nitrofurantoin PO daily on days 1-30. Patients complete a drug diary for each day they receive the antibiotic.
Drug: Clindamycin · Other: Diary · Drug: Ertapenem · Drug: Levofloxacin · Drug: Nitrofurantoin · Drug: Trimethoprim-Sulfamethoxazole
Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care.
Drug: Clindamycin · Drug: Ertapenem · Drug: Levofloxacin
Given PO
Also known as: Cleocin
Complete drug diary
Given PO
Given PO
Also known as: (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid Hydrate (2:1), Levaquin, Levofloxacin Hydrate, Quixin
Given PO
Also known as: Macrobid, Macrodantin
Given PO
Also known as: Bactrim, Bactrim DS, Bactrimel, Centran, Centrin, Co-Trimoxazole, Cotrim, Cotrimoxazole, Eslectin, Insozalin, Septra, SMZ-TMP, Sulfamethoprim, Sulfatrim, Sulmeprim, TMP-SMX, Trimedin, Trimezole, Uroplus
Number of Participants With Urinary Tract Infection (UTI)
The number of paticipants who experienced UTI (primary outcome) within 90 days after cystectomy is reported for each group.
Time frame: At 90 days after surgery
Number of Participants With Infection
Number of participants who experienced infectious complication(s) within 90 days after cystectomy is reported for each group. This includes UTI (primary outcome) and other types of infections, such as intraabdominal infection, wound infection, fungal infection, etc.
Time frame: Up to 90 days after surgery
The length of the recruitment ranges from 2020 to 2023, it is about 4 years. We recruited our patients in our department in Roswell Park Comprehensive Cancer Center. Patients who were scheduled cystectomy and eligible for this protocol were consented.
| Milestone | Group II (Standard of Care) | Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin) |
|---|---|---|
| Started | 45 | 44 |
| Completed | 40 | 37 |
| Not completed | 5 | 7 |
The number of paticipants who experienced UTI (primary outcome) within 90 days after cystectomy is reported for each group.
| Participants | Group II (Standard of Care) | Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin) |
|---|---|---|
| Number of Participants With Urinary Tract Infection (UTI) | 10 | 0 |
Number of participants who experienced infectious complication(s) within 90 days after cystectomy is reported for each group. This includes UTI (primary outcome) and other types of infections, such as intraabdominal infection, wound infection, fungal infection, etc.
| Participants | Group II (Standard of Care) | Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin) |
|---|---|---|
| Number of Participants With Infection | 17 | 5 |
Collected over Day of Cystectomy to Day 90 postop.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group II (Standard of Care) | 5/40 (12.5%) | 16/40 (40%) | 18/40 (45%) |
| Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin) | 0/37 (0%) | 8/37 (21.6%) | 24/37 (64.9%) |
| Event | Group II (Standard of Care) | Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin) |
|---|---|---|
| Small Bowel ObstructionGastrointestinal disorders | 3/40 | 0/37 |
| Urinary LeakageRenal and urinary disorders | 1/40 | 2/37 |
| Acute Kidney InjuryRenal and urinary disorders | 2/40 | 0/37 |
| Intraabdominal Infection/AbscessInfections and infestations | 2/40 | 1/37 |
| SepsisInfections and infestations | 2/40 | 0/37 |
| Psychosis Confusion/DepressionNervous system disorders | 2/40 | 0/37 |
| pleural effusionsRespiratory, thoracic and mediastinal disorders | 2/40 | 0/37 |
| UTI (SAE)Infections and infestations | 2/40 | 0/37 |
| Iatrogenic low rectal injuryGastrointestinal disorders | 0/40 | 1/37 |
| Vesicovaginal FistulaRenal and urinary disorders | 0/40 | 1/37 |
| Event | Group II (Standard of Care) | Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin) |
|---|---|---|
| UTI (Normal AE)Infections and infestations | 8/40 | 0/37 |
| HyperkalemiaMetabolism and nutrition disorders | 4/40 | 6/37 |
| MalnutritionMetabolism and nutrition disorders | 0/40 | 5/37 |
| DiarrheaGastrointestinal disorders | 5/40 | 2/37 |
| AnemiaMetabolism and nutrition disorders | 5/40 | 2/37 |
| ArrhythmiaCardiac disorders | 2/40 | 4/37 |
| AcidosisMetabolism and nutrition disorders | 4/40 | 4/37 |
| DehydrationMetabolism and nutrition disorders | 2/40 | 4/37 |
| Deep Venous ThrombosisVascular disorders | 3/40 | 2/37 |
| Wound InfectionInfections and infestations | 2/40 | 0/37 |
| Age, Continuous(years) | Group II (Standard of Care) | Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin) | Total |
|---|---|---|---|
| Median | 68 (64 to 77) | 70 (65 to 75) | 69 (65 to 76) |
| Sex: Female, Male(Participants) | Group II (Standard of Care) | Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin) | Total |
|---|---|---|---|
| Female | 14 | 5 | 19 |
| Male | 26 | 32 | 58 |
| Race/Ethnicity, Customized(Participants) | Group II (Standard of Care) | Group I (Trimethoprim-sulfamethoxazole, Nitrofurantoin) | Total |
|---|---|---|---|
| African American/Black | 0 | 3 | 3 |
| Other Race/Ethnicity | 40 | 31 | 71 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2020 to primary completion in Mar 2025, 54 months.
Results were first posted in Sep 2026, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitrofurantoin
Roswell Park Cancer Institute →